Sandoz Group EBIT par action

Que fait Sandoz Group ? Sandoz Group AG generates revenue through its Generics and Biosimilars businesses. The Generics business develops, manufactures, and markets active ingredients and finished dosage forms of small molecule pharmaceuticals, as well as anti-infective finished dosage forms and active pharmaceutical ingredients. The Biosimilars business develops, manufactures, and markets protein-based biological products similar to already approved biological medicines. Sandoz serves customers worldwide across therapeutic areas including cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory treatments. Its product portfolio covers all major treatment areas for patient care. The company's Generics business focuses on small molecule pharmaceuticals and anti-infectives, while Biosimilars targets protein-based biological products. Both segments serve global healthcare markets with products for various therapeutic areas. Sandoz's customers are healthcare providers and institutions worldwide that require pharmaceutical solutions for diverse medical conditions. Sandoz Group AG's revenue streams come from the sale of generics and biosimilars across all therapeutic areas. The company's products are distributed globally to healthcare systems and providers who treat patients in cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory conditions. The firm's business model relies on developing and commercializing both small molecule pharmaceuticals and biological products to meet global healthcare needs. Sandoz Group est l'une des entreprises les plus populaires sur Eulerpool.